Journal of Crystallization Process and Technology

Vol.4 No.1(2014), Paper ID 41735, 4 pages

DOI:10.4236/jcpt.2014.41004

 

The Polymorphism and Transformation of (3aRS, 4RS, 7RS, 7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyisoindoline-1,3-dione (SU2162)—A Novel Anticancer Compound

 

Yuqing Huang, Zaiyou Tan, Lin Luo, Hui Yang, Chunmei Tong, Wenfei Chen, Tingyu Huang, Ruiling Liu

 

School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.

 

Copyright © 2014 Yuqing Huang, Zaiyou Tan, Lin Luo, Hui Yang, Chunmei Tong, Wenfei Chen, Tingyu Huang, Ruiling Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

 

How to Cite this Article


Y. Huang, Z. Tan, L. Luo, H. Yang, C. Tong, W. Chen, T. Huang and R. Liu, "The Polymorphism and Transformation of (3aRS, 4RS, 7RS, 7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyisoindoline-1,3-dione (SU2162)—A Novel Anticancer Compound," Journal of Crystallization Process and Technology, Vol. 4 No. 1, 2014, pp. 27-30. doi: 10.4236/jcpt.2014.41004.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.